tozorakimab

Tozorakimab Report

Name: tozorakimab Name (English): tozorakimab

Description: Tozorakimab (MEDI-3506) is a high-affinity human immunoglobulin G1 monoclonal antibody that neutralizes interleukin-33 (IL-33). IL-33 is a cytokine involved in inflammatory processes. By blocking IL-33 signaling through its receptors ST2 and RAGE/EGFR, tozorakimab aims to reduce inflammation and epithelial dysfunction.

Mechanism of Action: Tozorakimab inhibits both reduced (IL-33red) and oxidized (IL-33ox) forms of IL-33, preventing them from binding to their respective receptors (ST2 and RAGE/EGFR complex). This action reduces downstream signaling that leads to inflammation.

Investigational Uses: Tozorakimab is currently under investigation for the treatment of various inflammatory conditions, including:

• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Viral Lung Infections
• Atopic Dermatitis (discontinued)
• Diabetic Nephropathies (discontinued)

Administration:

• COPD: Subcutaneous injection at regular intervals.
• Viral Lung Infections: Single intravenous (IV) dose.

Clinical Trial Status: Tozorakimab is in various phases of clinical development:

• Phase 3: COPD, Respiratory Insufficiency, Viral Lung Infection.
• Phase 2: Asthma.
• Phase 1: Pharmacokinetic trial in healthy adults.

Potential Benefits Studied:

• Reduction in COPD exacerbations.
• Improvement in lung function (FEV1).
• Enhanced quality of life for COPD patients.
• Decreased need for rescue medications in COPD.
• Prevention of death or progression to mechanical ventilation in severe viral lung infections.
• Reduction in duration of hospital stays and ICU time for viral lung infections.